Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary InterventionResults of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study
Giuseppe Patti, MD, FACC,
Annunziata Nusca, MD,
Fabio Mangiacapra, MD,
Laura Gatto, MD,
Andrea D'Ambrosio, MD and
Germano Di Sciascio, MD, FACC*
Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Rome, Italy
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 The ARMYDA-PRO Study—Primary End Point
Incidence of primary end point (30-day major adverse cardiac events [MACE]) according to quartile distribution of pre-intervention platelet (P2Y12) reaction units (PRU) values. ARMYDA-PRO = Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome. Figure illustration by Rob Flewell.
|
|
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 The ARMYDA-PRO Study—Secondary End Points
Distribution of pre-intervention PRU levels according to post–percutaneous coronary intervention creatine kinase-myocardial band (CK-MB) (A) and troponin-I (Tn-I) (B) values. Abbreviations as in Figure 1. Figure illustration by Rob Flewell.
|
|
|
